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Abstract: Various criteria are necessary to assess the efficacy and safety of biological 
 medications in order to grant companies the right to register these medications with the 
appropriate bodies that regulate their sale. The imminent expiration of the patents on reference 
biological products which block the cytokine TNF-α (tumor necrosis factor-α) raises the pos-
sibility of bringing so-called biosimilars to the market (similar to the biologicals of reference 
products). This occurrence is inevitable, but criteria to adequately evaluate these medications 
are now needed. Even among controversy, there is a demand from publications correlating the 
pro-apoptotic mechanism of the original TNF-α antagonists (etanercept, infliximab, adalimumab, 
golimumab, and certolizumab pegol) in the treatment of rheumatoid arthritis and other diseases. 
In this article, the authors discuss the possibility of utilizing the pro-apoptotic effect correlated 
with the regulation of the anti-apoptotic proteins FLIP and NF-κB as new criteria for analyzing 
the pharmacodynamics of possible biosimilar TNF-α antagonists which should be submitted to 
regulatory agencies for evaluation.
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Introduction
In the mid-80s and the early 90s Tumor necrosis factor-alpha (TNF-α), a soluble or 
transmembranal cytokine, became a promising candidate for the treatment of rheu-
matoid arthritis (RA).1 A direct relation was determined between this cytokine and 
pro-inflammatory signaling, which results in the migration of immune system cells 
to the synovial region, producing chronic synovial inflammation, bone erosion, and 
cartilage damage.2
Preclinical and clinical studies show that blocking the cytokine TNF-α reduced not only 
the inflammation of RA, but also the progression of intestinal inflammation  characteristic 
of Crohn’s Disease (CD).3–5 As a result, the industry proposed development of medica-
tions which function as TNF-α antagonists. Now these biologicals, which belong to the 
class of disease-modifying anti-rheumatic drugs (DMARDs), are part of the therapeutic 
arsenal against RA and spondyloarthritis. Currently, the main TNF-α antagonists available 
are etanercept (ENBREL®; Amgen and Wyeth, Thousand Oask, CA, USA), infliximab 
(REMICADE®; Janssen Biotech, Mitsubishi Tanabe Pharma and Merck & Co, Inc., 
Whitehouse Station, NJ, USA), adalimumab (HUMIRA®; Abbott Laboratories, Abbott 
Park, IL, USA), certolizumab pegol (CIMZIA®; Union chimique belge, Brussels, Belgium) 
and golimumab (SIMPONI®; Centocor Ortho Biotech Inc., Horsham, PA, USA).6
Due to the expiration of the patents on TNF-α antagonist medications, an 
 opportunity has arisen for various manufacturers to produce so-called biosimilar 
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versions of these molecules. These are, in theory, similar 
to the standard biopharmaceuticals, but not identical. In 
order to protect consumers from possible damage caused by 
these copies, strong criteria are required for analyzing these 
molecules and conducting studies that demonstrate their 
effectiveness and safety.
Assessing the bioequivalence and biocomparability of 
a protein produced by two different manufacturers can be a 
challenge for regulating agencies. The criteria for analyzing 
each case are crucial to the perceived efficacy and safety of 
the medication.7
Currently, various clinical and non-clinical assessments 
are used to evaluate the efficacy of these TNF-α blockers. 
While the mechanism by which TNF-α antagonists act is 
not yet completely clear, there are studies correlating these 
 medications with the occurrence of cellular apoptosis. The 
action of these antagonists with receptors of cell death prohib-
its the expression of some anti-apoptotic proteins in RA.
Most notable among these inhibitory proteins is FLIP 
(FLICE-like inhibitory protein, where FLICE is a FADD-
like interleukin-1 beta-converting enzyme, FADD is a Fas-
associated death domain protein and Fas is a death receptor 
[also known as CD95 and APO-1]). FLIP is a protein which 
inhibits caspase-8, impeding the uptake of this caspase for 
the death-inducing signaling complex (DISC) and thereby 
inhibiting apoptosis. Another important inhibitory protein, 
NF-κB (nuclear factor kappa-light-chain- enhancer of activated 
B-cells), promotes the expression of anti-apoptotic genes, 
resulting in the production of the proteins TRAF1, TRAF2, 
cIAP-1, cIAP2 and FLIPL.8–10
A potential correlation between the apoptotic mechanisms 
of the TNF-α antagonists which are already on the market 
and their respective biosimilars would allow the criteria for 
evaluating the copies to be expanded. In the meantime, as 
will be discussed in this article, apoptosis may have distinct 
repercussions on each TNF-α antagonist under various 
experimental conditions.
The objective of this article is to discuss the importance 
of the apoptosis mechanism and of the proteins FLIP and 
NF-κB as criteria for analyzing the pharmacodynamics of 
possible biosimilar TNF-α antagonists.
Biosimilars: perspectives  
and methods of registration
It is well-known that biological medications are tested more 
often (eg, preclinical studies and clinical trials) than chemi-
cal medications (produced by chemical synthesis). These 
molecules are more complex because they are produced 
by biotechnological processes based on living organisms. 
The majority are proteins with high molecular weights, 
unstable, and are more likely to cause adverse immunologi-
cal reactions.11 The complexity is such that the same protein 
produced by one particular company may have structural 
variations from one batch to the next.
After a patent expires, specific information such as 
the production line, and principally, the master cell line 
are the exclusive property of the company that holds the 
 patent.  Consequently, it is impossible to consider biological 
 medications as “generics”, but instead “biosimilars” which 
are similar in structure, functionality, efficacy, and safety to 
the patented medications.
The need for and importance of these two classes of 
 medication are indisputable. The original or reference biolog-
icals are the trailblazers of innovation in the  pharmaceutical 
industry which should be constant. Yet, at the same time, 
biosimilars are a path to high-quality treatment at a low cost 
in order to increase the access to biologics, especially in 
developing countries.12
A reference biological, as a rule, undergoes strict 
assessment. Its eff icacy and safety are demonstrated 
in a full dossier that contains preclinical tests such as 
 molecular quality,  pharmacokinetics (absorption, distribu-
tion, biotransformation and excretion), pharmacodynam-
ics  (mechanism of drug action), and acute and chronic 
toxicity studies in animals in the first stage. In the next 
step, phase I, II, III, and IV clinical trials are conducted; 
immunogenicity and clinical safety are assessed, and a phar-
macovigilance plan is developed.13,14
In terms of biocomparability, evaluation criteria should 
establish the correlation, within an acceptable margin, between 
quality, safety, and efficacy in order to demonstrate the similar-
ity between a reference molecule and a biosimilar.
The US Food and Drug Administration (FDA) and the 
 European Medicines Agency (EMA) have determined the fol-
lowing basic regulatory principles for approval of  biosimilar 
molecules: a dossier describing the manufacture and quality 
of the molecule, preclinical studies, clinical studies, and 
immunogenicity and pharmacovigilance studies.15,16
The planning of clinical studies to detect differences 
between the reference molecule and the biosimilar is a 
 crucial factor in measuring comparability, especially studies 
of equivalency and non-inferiority.17
Among the variables explored by comparability  studies, 
the pharmacodynamics of the reference molecule are 
 important in evaluating similarity; as a result, it is necessary 
to understand the mechanism of action.
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In the context of TNF-α antagonists, the basic 
 pharmacodynamics are characterized by the neutralization 
of soluble or transmembranal TNF, which results in the 
anti-inflammatory action that demonstrates the benefits of 
this treatment. The interaction between these biologicals 
and the complement system is also assessed, by  recognition 
of the Fc portion (fragment crystallizable, in the cases of 
the monoclonal antibodies infliximab, adalimumab and 
golimumab).
The increase in apoptosis in RA and CD correlated 
with inhibition of FLIP and NF-κB proteins in RA can be 
 considered as criteria for defining comparability studies 
between the reference molecule and its biosimilar. This 
proposal is based on references in the literature which 
affirm that apoptotic action can be a specific effect of some 
TNF-α antagonists, and its possible means of action could 
be through neutralization of FLIP and NF-κB proteins by a 
reverse signal.3,15–21
TNF-α antagonists and apoptosis
To better understand the process which results in apoptosis, 
Micheau and Tschopp22 described the two main pathways for 
the occurrence of cellular death or survival (Figure 1).
During the inflammatory response, the cytokine TNF-α 
can act by means of binding to transmembranal TNFR1 and 
2 receptors in some cells in the immune system, transmit-
ting survival signals (apoptosis inhibitors), the route of 
inflammation, and routes promoting mitosis. As a result, it 
is well-known that in RA, low levels of cellular apoptosis 
occur in the joints and synovial fluid.23 Studies reveal that 
the interaction of soluble TNF-α is more accentuated with 
TNFR2 which, more than TNFR1, possesses an ambiguous 
characteristic24 (Figure 1), activating the apoptosis pathway 
or activating the cellular survival pathway depending on 
the external signal, on the adaptation proteins present in 
the cytosol, and on other factors which have not yet been 
determined.25
During the past decade, various studies related to 
TNF-α antagonists demonstrated that the use of etaner-
cept, infliximab, adalimumab and certolizumab pegol not 
only reduces serum levels of TNF-α, the immune response 
promoter, but also promotes the death of some inflamma-
tory cells. This death occurs by reactivation of the apoptotic 
pathway, providing greater efficacy in treatment. However, 
each TNF-α antagonist responds differently with relation 
to apoptosis. Table 1 shows the specifics of each TNF-α 
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Figure 1 Signaling pathways of the cytokine TNF-α.
Notes: Soluble TNF-α binds to TNFR1 and 2 receptors, resulting in the uptake of the proteins TRADD, RiP1, and TRAF2, forming Complex i. when this complex 
dissociates, the death domains (DD) of TRADD and RiP1 are liberated and bind to FADD. FADD in turn recruits caspases 8 and 10, forming Complex ii and culminating in 
apoptosis. if NF-κB is activated, promoted by Complex i, there will be an accentuated production of FLiPL, inhibitor which blocks caspase 8, impeding apoptosis, promoting 
survival and the production of inflammatory cytokines. Reprinted from Cell. 114(2), Micheau O, Tschopp J. induction of TNF receptor i-mediated apop tosis via two sequential 
signaling complexes, Page 188.22 © 2003 with permission from elsevier.
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inhibitor, highlighting the potential of each to promote 
cellular apoptosis.
Lügering et al21 in turn have identified a possible relation 
between the action of infliximab on cellular apoptosis in 
patients suffering from CD. They observed that 4 hours after 
administration of infliximab, monocyte apoptosis occurred, 
as determined by assessing the activation of caspases 8, 9, 
and 3, which act independently of signaling from CD95/95L 
(CD95 and ligand) receptors.
Di Sabatino et al43 conducted experiments in which they 
administered infliximab to patients with CD. The patients 
received the medication over 10 weeks at a concentration 
of 5 mg/kg. After treatment, it was verified that infliximab 
promoted apoptosis by increasing the susceptibility of lamina 
propria cells to peripheral blood T-cells. In in vivo and in 
vitro studies, the results also indicated that the mechanism 
of apoptosis is initiated by dependent caspase and not by the 
interaction receptor Fas-Fas in CD.
Ohshima et al44 assessed the action of TNF-α antagonists 
based on studies of treatment of synovial hyperplasia (an 
event characteristic of RA). The authors demonstrated that 
treatment can promote the reactivation of CD95 receptors 
(death receptors), which are crucial in the apoptotic process 
as they facilitate cellular apoptosis.
The authors demonstrated that the chimeric monoclo-
nal antibody (infliximab) activated another death pathway 
through other receptors such as TNFR1. Meusch et al45 
studied the blocking of TNF-α expression and of cellular 
apoptosis by means of TNF-α antagonists in in vitro studies 
using samples of peripheral blood monocytes taken from 
patients with RA. They demonstrated a significant increase 
in cellular apoptosis, reduction of TNF-α, and a possible 
drug intervention by means of interaction with the TNFR 
receptors.
Clinical tests of infliximab and etanercept in patients 
with CD demonstrated that these molecules can attach 
to the transmembranal TNF (tmTNF) of some inflam-
matory cells, mainly in monocytes found in tissue and 
synovial fluid. After attaching, they transmit an intracel-
lular signal; apoptosis is one of the possible results of this 
interaction.46,47
Pattacini et al48 also demonstrated the correlation between 
the effectiveness of TNF-α antagonists and apoptosis and 
concluded that etanercept has a stronger pro-apoptotic 
effect. In vitro experiments were conducted, in which TNF-α 
antagonists were administered into cells cultured from 
fibroblasts (synovioctyes) and peripheral blood monocytes 
collected from patients with RA. The results demonstrated 
activation of cellular apoptosis in these cell types, which are 
crucial in the progression of RA.
Catrina et al20 evaluated patients with RA with regards 
to the relation between the TNF-α antagonists etanercept 
and infliximab and apoptosis. The authors concluded that 
these medications promote an increase in apoptosis in CD14 
cells such as macrophages, dendritic cells and synovial fluid 
mononuclear cells (SFMCs). Furthermore, they stated that 
the possible cause of apoptosis could be due to the regula-
tion of the proteins FLIP and NF-κB.8 However, it was 
stressed that etanercept does not induce apoptosis in lym-
phocytes, only in macrophages. In other studies, high doses 
of infliximab promoted apoptosis in both lymphocytes and 
macrophages, but doses of 3 mg/kg resulted in the decrease 
of macrophages only.49
Shen et al37 in turn concluded that adalimumab and 
infliximab affect the production of monocyte cytokines 
and induce apoptosis in activated monocytes. It was also 
demonstrated that adalimumab can activate the caspase 3 
pathway, resulting in a higher level of cellular apoptosis in 
treated chimeric rats. The results finally show that cellular 
apoptosis can be blocked by the pan-caspase inhibitor, assur-
ing that adalimumab’s apoptosis mechanism is independent 
of caspase.
Herman et al50 verified the pro-apoptotic action of TNF-α 
antagonists in a clinical study. Fifteen patients with RA 
were administered TNF-α antagonists together with metho-
trexate, 20 patients received only methotrexate, and eleven 
patients did not receive any treatment. A significant increase 
in cellular apoptosis in T-helper 1 and T-helper 2 (Th1/Th2) 
lymphocytes was noted; this amplif ied inflammation, 
resulting in significant reduction of joint inflammation and 
restoration of the balance of Th1/Th2 lymphocytes.
Experiments conducted by Aravena et al51 demonstrated 
that treatment with the TNF-α antagonist adalimumab over a 
period of 16 weeks in patients with RA promoted a population 
balance of the CD4 Th 1, and Th 17 lymphocytes population. 
There was also a reduction in secretion of interferon gamma 
(IFN-γ) by CD8, indicating that it is not apoptosis itself that 
promotes reduction of the inflammatory process, but instead 
the apoptosis of specific cells which play an important role 
in the process of chronic inflammation.
The important connection between the Fc fragment of 
the monoclonal antibodies infliximab, adalimumab and 
golimumab and the cellular depletion pathways has also 
been determined. It has been proposed that there is a certain 
dependence on this fragment in the pro-apoptotic process of 
these molecules. The exception is golimumab, which despite 
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possessing the Fc fragment has not yet shown a relationship 
with the apoptotic process.52 These data have been confirmed 
by Bourne et al,41 who have proposed the hypothesis that 
apoptosis is not a clinically effective action in CD, consider-
ing that etanercept promotes apoptosis but is not effective in 
treating CD. While certolizumab pegol does not have Fc, it 
does not promote apoptosis, but is effective in the treatment 
of CD. Yet etanercept, even with Fc, does not promote the 
activation of the complement system,53 and certolizumab 
pegol promoted apoptosis in a study by Atreya et al.19 As a 
result, dependency on the Fc fragment in this mechanism is 
questionable.
Van den Brande et al,40 in turn, stressed that etaner-
cept did not induce apoptosis in in vitro experiments with 
T lymphocytes in patients with CD. In another study, Fries 
et al54 administered etanercept and infliximab to rats with 
colitis and determined that both of these TNF-α antagonists 
reduced the population of enterocytes by apoptosis, probably 
as a result of the reduction of circulating TNF-α.
In a recent study, Eder et al55 demonstrated in an in vitro 
study with mononuclears and enterocytes of patients with 
CD, that infliximab and adalimumab exert a pro-apoptotic 
influence, producing an increase in the pro-apoptotic proteins 
Bax/Bcl-2 which assist in the process of apoptosis. The 
authors also stress that the efficiency of the TNF-α antagonist 
depends, at least in part, on this process. This study corrobo-
rates data from Van den Brande et al.40 There are drawbacks 
to the use of apoptosis such as clinical effectiveness of TNF-α 
antagonists in CD and in RA, but certainly the pharmacody-
namics of TNF-α antagonists carry out apoptosis.
It should also be taken into account that the in vitro 
studies with RA and CD obtained more favorable results in 
comparing the action of TNF-α antagonists to the apoptotic 
mechanism. Nevertheless, Makrygiannakis and Catrina18 
do not consider apoptosis as a criteria for the clinical 
 effectiveness of TNF-α antagonists in RA, as all antagonists 
have similar efficacy but different apoptotic effects. This 
shows that in theory, apoptosis is not fundamental to the 
treatment of RA, but is a criteria for extrapolation of treat-
ment and certainly for the pharmacodynamics of TNF 
antagonists. There are still many doubts and questions to be 
discussed in order to define apoptosis as a clinically effective 
treatment process; for this reason, more studies should be 
conducted in this area.
The pro-apoptotic effect, in the context of treating chronic 
inflammation, is not restricted to only TNF-α antagonists. 
Some non-biological medications classified as DMARDS 
promote apoptosis in specific cells by modulating actions 
on the expression of anti-apoptotic proteins such as FLIP, 
families of X-linked inhibitor of apoptosis protein (XIAP), 
inhibitors, execution caspases, and  survivins. According to 
Smith et al,56 elevated levels of FLIP, XIAP, and survivins 
were detected in samples taken from patients with RA. 
However, 6 weeks after beginning treatment with DMARDS, 
analysis showed that the levels of these inhibitors fell steeply, 
causing a substantial increase in apoptosis in synovial cells. 
Other studies showed the pro-apoptotic action of DMARDS 
(non-biologicals) such as sulfasalazine,57 and hydroxichlo-
roquine.58 Methotrexate, which in many cases is used in 
conjunction with TNF-α antagonists, and cyclophosphamide 
also promote cellular apoptosis in activated T CD4 and CD8 
cells, but not in resting cells, through CD95 sensitivity.59,60
Research on the pro-apoptotic effect of TNF-α  antagonists 
heavily focuses on RA and CD, but there are also studies with 
psoriatic arthritis (PsA) and psoriasis (Ps).61,62
FLIP and NF-kB proteins
Among the various possible routes, one probable pathway for 
the pro-apoptotic action of TNF-α antagonists in RA could 
be related to the inhibited expression of FLIP and NF-κB 
proteins, which are abundant in RA and fundamental to the 
process of inflammation.
Perlman et al63 have investigated the relation between 
FLIP in monocytes treated with lipopolysaccharide (LPS) 
and TNF-α. The authors showed that there was a significant 
increase in the expression of FLIP and a reduction in the 
expression of Fas-FasL (Fas and ligand), protecting the 
monocytes from apoptosis.
Further, they stated that after blocking FLIP through 
specific oligonucleotides, there was subsequently a return of 
sensitivity to apoptosis in the monocytes. The authors  propose 
that the action of LPS and TNF-α in reducing  apoptosis is 
associated with the FLIP protein.
Palao et al64 demonstrated that low regulation of the 
FLIP protein strongly affects the population of synovial 
 fibroblasts through apoptosis, mediated by Fas receptors. 
They  suggest the existence of a reverse pro-apoptotic signal 
after the inhibition of FLIP. Schedel et al65 also propose that 
the expression of FLIP in the synovial tissue in RA is related 
to the accumulation of inflammatory cells, indicating that 
FLIP may potentially be responsible for the extension of 
the life of synovial cells, and accordingly may contribute 
to the progression of articular damage. To arrive at this 
 conclusion, the expression of mRNA for synthesizing the 
FLIP protein was analyzed in five samples of synovial 
tissue from patients with RA, two samples from patients 
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with osteoarthritis (OA), and two samples from healthy 
volunteers. At the end of the study, the expression of mRNA 
was observed only in the tissue samples from patients with 
RA and OA, and was not detected in the samples from 
healthy volunteers; this  demonstrated a relevant connection 
between the apoptotic action of the FLIP protein with the 
progression of RA.
Wu et al,66 in analyzing eleven samples from patients with 
juvenile idiopathic arthritis (JIA) and three samples from 
healthy volunteers using the RC-PCR technique (reverse 
transcriptase polymerase chain reaction), verified that in all 
patient samples the expression of mRNA FLIP was pres-
ent, while in the normal samples there was no considerable 
expression. This demonstrated that an elevated incidence of 
this protein could promote a longer life for synovial cells, 
boosting inflammation.
Elevated levels of FLIP are directly related to the 
expression of NF-κB9 characterized by a protein com-
plex which acts as a transcription factor in B-cells as 
RA progresses.67 A common characteristic of RA is 
the activation of NF-κB68 which functions to transcribe 
 pro-inflammatory genes in immune responses, cellular 
growth and development processes, protecting monocytes 
and macrophages from apoptosis. In this way the reduc-
tion of NF-κB can consequently promote apoptosis in 
macrophages and in  monocytes after treatment with TNF-α 
antagonists.69 Blocking NF-κB in RA synovial fluid cells 
lowered regulation of the FLIP-L genes,70  suggesting 
that reverse signaling could also promote apoptosis with 
dependent caspase.
There is evidence that pro-inflammatory cytokines such as 
TNF-α and IL-1 work by activating NF-κB  dependent path-
ways which play an important role in synovial  proliferation, 
leukocyte infiltration, and the synthesis of other pro-
 inflammatory mediators.71,72
The moment at which FLIP and NF-κB, as key factors 
in the pathology of RA, approach and encounter the pro-
apoptotic mechanism of TNF-α antagonists is described by 
Makrygiannakis and Catrina.18 They stress that the modula-
tion of NF-κB promotes the reduction in expression of FLIP, 
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Notes: The TNF-α antagonists may interact with the transmembranal receptor TNFR2, promoting a reverse signal which blocks the NF-κB pathway, resulting in the 
blockage of FLiP. in this way caspase 8 is activated to unlock the caspase 3 cascade which initiates apoptosis. Furthermore, there is the pro-apoptotic signal from the 
mitochondrial pathway, where the reverse signal activates the p53 protein; this protein recruits proapoptotic proteins such as bcl-2 which interact with cytochrome C, which 
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after utilization of the TNF-α antagonists, resulting in a 
reverse signal, which culminates in apoptosis (Figure 2). They 
also describe the possible relationship between the reverse 
signal and the modulation in expression of p53 (tumor sup-
pressing protein) and pro-apoptotic proteins, such as Bcl-2 
and cytochrome C, for the formation of the  apoptosome and 
activation of apoptosis.
Conclusion
In the context of studies comparing a reference molecule 
and a biosimilar, certainly the individual data regarding 
the  promotion of apoptosis by etanercept, infliximab, 
 adalimumab and certolizumab pegol (to a lesser extent), 
should be taken into consideration. However, there is a need 
to standardize experiments, keeping in mind that in the 
literature, the pro-apoptotic action of the antagonists varies 
in accordance with various factors such as the quantity of 
the biological administered, the length of treatment, and the 
type of disease. In this way, a more accurate analysis with 
regards to the apoptotic mechanism can be considered, as one 
of the main apoptosis pathways used by TNF-α antagonists is 
dependent on caspase 3, which in turn is strongly influenced 
by FLIP (expressed by NF-κB), the suppressor of caspase 8 
(activator of caspase 3). The reverse signal promoted by the 
TNF-α antagonists could be an action mechanism that should 
be explored in comparability studies in the context of RA.
As the costs of biosimilar medications drop, there 
is an overall expectation, especially from governmental 
organizations in many countries, that there will be an increase 
in prescriptions of these medications compared to the refer-
ence biologicals. Nevertheless, it should be stressed that proof 
of the efficacy and safety of biosimilars is the sine qua non 
condition for their use and sale.
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